Sept 8 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES ANNOUNCES RESUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR RYPLAZIM® (PLASMINOGEN) FOR TREATMENT OF CONGENITAL PLASMINOGEN DEFICIENCY
* LIMINAL BIOSCIENCES INC - RESULTS FROM PIVOTAL PHASE 2/3 STUDY MET CO-PRIMARY ENDPOINTS
* LIMINAL - BELIEVES AMENDED BLA REPRESENTS A CLASS 2 RESUBMISSION THAT WOULD PROVIDE FOR PDUFA DATE WITHIN 6 MONTHS FROM DATE OF RESUBMISSION